Q-omics provides the consensus-scored NDUFA6 profile across patient tissues and cancer cell-line models. NDUFA6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NDUFA6 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, NDUFA6 protein abundance shows 19,033 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, LIHC, and GBM as cancer lineages where NDUFA6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFA6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFA6 survival associations across molecular data types. NDUFA6 RNA expression shows survival associations in the most cancer types (26), followed by mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFA6 RNA expression–survival associations across cancer types. High NDUFA6 expression shows unfavorable associations in UVM, ACC, UCS and LIHC, but favorable associations in KIRP and UCEC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NDUFA6 RNA expression.
This table summarizes NDUFA6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDUFA6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFA6 shows lower tumor expression in THCA and KIRC and higher tumor expression in LIHC, BRCA, LUSC and CHOL. The LIHC box plot shows higher NDUFA6 RNA expression in tumor versus normal tissue (log2 FC = +1.054, t-test p < 0.001).
This table shows molecular features associated with NDUFA6 in patient tissues and cancer cell lines. In patient samples, NDUFA6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NDUFA6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
